A
Arch Venture Partners, L.P.
+ HoldingQTTB
+13.15%
3M Return
$14.360
-0.493 (-3.43%)終値時点
Loading chart…
- High
- 14.760
- Open
- 14.750
- VWAP
- 14.44
- Vol
- 331.25K
- Mkt Cap
- —
- Low
- 14.190
- Amount
- 4.78M
- EV/EBITDA, TTM
- 0.00
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
バリュエーション指標
The current forward P/E ratio for Q32 Bio Inc (QTTB) is -0.41, compared to its 5-year average forward P/E of -4.27.
Whales holding QTTB
イベントタイムライン
ニュース
1.009-01PRnewswireQ32 Bio to Participate in Three Investor Conferences
6.008-24CNBCLatest Wall Street Rating Updates
9.508-05seekingalphaQ32 Bio Reports Narrower Q2 Loss, Shares Up 1.5%
8.508-05PRnewswireQ32 Bio Reports Positive Clinical Trial Results for Bempikibart
9.508-05seekingalphaQ32 Biopress Reports Q2 Earnings and Equity Raise
QTTB FAQ — answered by Alphio AI
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。